A weekly dose of semaglutide, the key ingredient in blockbuster medications Ozempic and Wegovy, helped seven out of 10 patients newly diagnosed with type 1 diabetes stop taking insulin after three ...

Type 1 and type 2 diabetes are driven by very different mechanisms. In type 2 , cells in the pancreas that make insulin become less sensitive to blood sugar and produce less insulin in response.

An early study hints at an intriguing possibility: The weight-loss drug Ozempic might allow people newly diagnosed with Type 1 diabetes to drop their daily insulin shots.

Initially approved to treat Type 2 diabetes, Ozempic and Mounjaro also can help people with Type 1 diabetes lose weight and control their blood sugar levels, a new study finds. Top News U.S. News ...

BUFFALO, N.Y.— Treating newly diagnosed Type 1 diabetes patients with semaglutide (trade names Ozempic, Wegovy and Rybelsus) may drastically reduce or even eliminate their need for injected insulin.

CHICAGO -- Semaglutide (Ozempic) reduced glucose levels and weight among patients with type 1 diabetes and obesity, a randomized trial showed. In this 26-week, double-blind trial of 72 adults, 36% ...

Patients with type 1 diabetes could possibly cease daily insulin injections thanks to the “miracle” weight loss drug Ozempic originally developed to combat type 2 diabetes, Metro News reported ...

People with type 1 diabetes who need to lose weight can benefit from the blockbuster GLP-1 drug semaglutide currently approved only for type 2 diabetes, according to results from a small trial.

More people with type 1 diabetes are using GLP-1s like Ozempic and Zepbound, a new study found. Researchers attribute the high demand to rising rates of obesity among people with type 1 diabetes.

An early study hints at an intriguing possibility: The weight-loss drug Ozempic might allow people newly diagnosed with Type 1 diabetes to drop their daily insulin shots.